Effects of multiple-dose ponesimod, a selective S1P₁ receptor modulator, on lymphocyte subsets in healthy humans.

ABSTRACT: This study investigated the effects of ponesimod, a selective S1P₁ receptor modulator, on T lymphocyte subsets in 16 healthy subjects. Lymphocyte subset proportions and absolute numbers were determined at baseline and on Day 10, after once-daily administration of ponesimod (10 mg, 20 mg, and 40 mg each consecutively for 3 days) or placebo (ratio 3:1). The overall change from baseline in lymphocyte count was -1,292±340×10⁶ cells/L and 275±486×10⁶ cells/L in ponesimod- and placebo-treated subjects, respectively. This included a decrease in both T and B lymphocytes following ponesimod treatment. A decrease in naïve CD4⁺ T cells (CD45RA⁺CCR7⁺) from baseline was observed only after ponesimod treatment (-113±98×10⁶ cell

SUBMITTER: Jurcevic S 

PROVIDER: S-EPMC5207338 | biostudies-literature | 2017

REPOSITORIES: biostudies-literature